SCHEMBL4294428

SCHEMBL4294428

COC(=O)c1cc2cc[nH]c(=O)c2c2cc(-c3ccc(C(N)=O)cc3)ccc12

nearest known ligand 0.65

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.65
RIPK1 Q13546 1/20 0.43
NR4A2 P43354 1/20 0.40
PLAU P00749 1/20 0.39
PLAT P00750 1/20 0.39
MAP3K11 Q16584 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295703 0.89 CHEK1 (0.71) CHEK1NR4A2
SCHEMBL4300340 0.88 CHEK1 (0.69) CHEK1NR4A2
SCHEMBL4295657 0.86 CHEK1 (0.52) CHEK1RIPK1
SCHEMBL4300984 0.86 CHEK1 (0.64) CHEK1NR4A2
SCHEMBL4292128 0.86 CHEK1 (0.67) CHEK1NR4A2
SCHEMBL4296990 0.85 CHEK1 (0.65) CHEK1NR4A2
SCHEMBL4291211 0.84 CHEK1 (0.59) CHEK1
SCHEMBL4289505 0.82 CHEK1 (0.57) CHEK1RIPK1MAP3K11
SCHEMBL4287614 0.82 CHEK1 (0.64) CHEK1NR4A2
SCHEMBL4287879 0.82 CHEK1 (0.64) CHEK1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US claimed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A CHEK1 1/4885RIPK1 402/4885NR4A2 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.